Peptides for Longevity: What the Evidence Actually Shows in 2026

Do any peptides actually extend lifespan?

Legal status, stated plainly. As of September 8, 2026, nothing on this page is approved by any major regulator for slowing aging or lengthening life. Some are approved for other things: elamipretide for Barth syndrome, semaglutide for obesity and diabetes, rapamycin for transplant rejection and tesamorelin for belly fat buildup in people with HIV. Several were in the July 23 to 24, 2026 FDA pharmacy panel votes, covered in the FDA status tracker. Those votes are not approvals. Below, the evidence is sorted from strongest to weakest: proper studies in people; smaller or watching-only studies in people (including gene studies and studies of a parent molecule); animal; in a dish; and no study in people of any kind.

Two of those levels get mixed up all the time, and they shouldn't be. 'Not approved' says nothing about whether something works. A molecule can be unapproved because a study tested it and it failed, or because nobody ever applied. And 'no proper study' is not the same as 'no data from people'. For several rows below, there are studies that watched groups of people, gene studies or studies of the parent molecule, and the table names them.

One thing to know before you read a table like this. A proper study in a few hundred people costs millions. That money almost always comes from whoever will own the drug at the end. Nobody can own some of these. They are a natural piece of a body protein, or a recipe published decades ago, or something already sold cheap. So nobody pays for the study, and the research stops at animals. For those, a missing study tells you how drug research gets paid for. It tells you nothing about whether the stuff works. That cuts both ways, just as hard. With no study, something that does nothing and something that causes a rare harm both look like something with no reported problems. No evidence here really means no evidence, in both directions. It is not a quiet thumbs up.

Do GLP-1 drugs slow biological aging?

This is the most-talked-about longevity result of 2026, and the warnings come from the authors themselves: 'the post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability' (Nature Communications, 2026). It matters here because semaglutide is a peptide, is approved and has more proper studies in people than everything else on this page put together. Nobody knows if clocks moving over 32 weeks means anything a person would notice. A clock can move because fat and inflammation fell, not because aging slowed. Tirzepatide and retatrutide are compared in our GLP-1 field guide.

Senolytics and rapamycin: the non-peptide yardsticks

Neither is a peptide, but peptide sellers point to both. In people, PEARL gave healthy adults a dummy pill, 5 mg or 10 mg of pharmacy-made rapamycin weekly for 48 weeks. Side effects were about the same in all groups. Belly fat did not change. Women on 10 mg gained lean mass and reported less pain (Aging, 2025). A related drug, everolimus, made flu shots work about 20 percent better in older volunteers (Science Translational Medicine, 2014). The Mayo Clinic test of dasatinib plus quercetin was tiny and open, but it was the first to show worn-out cells can drop in people (EBioMedicine, 2019). In mice, rapamycin has the deepest record. The 2009 Nature study showed longer life at three separate test sites, in mixed-breed mice, even when feeding started at 600 days (Nature, 2009). How to read PEARL is argued in the rapamycin dosing debate.

Why growth hormone peptides run against the longevity biology

Sermorelin, ipamorelin, CJC-1295, MK-677 and tesamorelin all raise growth hormone, and with it IGF-1. The anti-aging pitch dates from the 1990s. The science has moved the other way since. Growth hormone given to healthy older adults, across 18 study groups, added 2.1 kg of lean mass, took off 2.1 kg of fat and caused clearly more side effects. The reviewers rejected it as an anti-aging treatment (Annals of Internal Medicine, 2007). The Guevara-Aguirre group followed roughly 100 people without working growth hormone receptors for 22 years. They 'exhibited only one nonlethal malignancy and no cases of diabetes, in contrast to a prevalence of 17% for cancer and 5% for diabetes in control subjects' (Science Translational Medicine, 2011). In mice, Brown-Borg reported that Ames dwarf mice, which lack growth hormone, live unusually long. It was the first proof that changing one gene could lengthen a mammal's life (Nature, 1996). The growth hormone-boosting peptides have never been tested for lifespan in any species.

What is the evidence for epitalon and thymalin?

Epitalon (Ala-Glu-Asp-Gly) is a lab-made peptide, four building blocks long, based on epithalamin, an extract of the pineal gland. Thymalin is an extract of the thymus gland. The human study reported deaths 2.0 to 2.1 times lower for thymalin, 1.6 to 1.8 times lower for epithalamin, 2.5 times lower for both, and 4.1 times lower in a group treated every year for 6 years (Neuroendocrinology Letters, 2003). It was an open study at one institute, with no dummy treatment. It used epithalamin, the extract, not the lab-made epitalon in the vials. And a drop in deaths that size would be unheard of for any treatment. That argues for repeating it, not believing it.

The mouse paper is careful. It says 'treatment with Epitalon did not influence food consumption, body weight or mean life span of mice'. The last 10 percent of survivors lived 13.3 percent longer, and chromosome damage in bone marrow fell 17.1 percent (Biogerontology, 2003).

Klotho, humanin and the mitochondrial peptides

Klotho is the best-backed aging target in animals, and it also has gene evidence in people that often gets dropped. People with one copy of the KL-VS version of the klotho gene, which raises klotho in the blood, did better on thinking tests (Cell Reports, 2014). A later review of five studies in 3,581 adults aged 60 to 80 with normal thinking found that among APOE4 carriers, KL-VS cut the odds of Alzheimer's plaque on a brain scan by roughly a third (odds ratio 0.67, likely range 0.52 to 0.88). It made no difference in people without APOE4 (Neurobiology of Aging, 2021). Gene studies are not treatment studies. They say the pathway matters in people, not that injecting anything helps. In mice, extra klotho made them live longer by turning down insulin and IGF-1 signals (Science, 2005). In old rhesus monkeys, one small dose improved memory for weeks (Nature Aging, 2023). Our klotho explainer covers what is sold under the name.

The pattern for the mitochondrial peptides is clever biology, strong rodent results and human evidence that only watches people or covers one rare disease. Elamipretide was approved only for Barth syndrome, based on thigh muscle strength, and the FDA wants a follow-up study to confirm it (FDA press release, September 19, 2025). Its failed big study in a mitochondrial muscle disease is covered in our SS-31 approval post. For humanin, 18 children of people who lived to 100 had more of it in their blood than 19 others (Aging, 2020). In worms, more humanin meant longer life. In middle-aged mice, a lab-made version called HNG, given twice a week, kept them healthier. MOTS-c is a peptide 16 building blocks long, made from mitochondrial DNA. In its first paper, it switched on the energy sensor AMPK and protected mice from insulin problems caused by age and a fatty diet (Cell Metabolism, 2015). Our MOTS-c evidence review tracks the first listed study in people.

GHK-Cu and FOXO4-DRI

GHK-Cu is a small copper-carrying peptide whose blood level falls with age. The 2015 review behind most of the ads lists collagen effects, wound healing in several species and skin results. It suggests GHK 'is capable of up- and downregulating at least 4,000 human genes' (Biomed Research International, 2015). In people, there are skin cream studies on how skin looks and how wounds heal. There is no study of any aging result, and none of the injected form people buy. FOXO4-DRI pulls apart two proteins (p53 and FOXO4) so that worn-out cells die off. There is no study in people of any kind, no listed study and no data on how the human body handles it. In 2017, it 'restored fitness, fur density, and renal function' in fast-aging and naturally old mice (Cell, 2017).

The bottom line

Sort the table by evidence in people, and the peptides pushed hardest for longevity land at the bottom. None of epitalon, thymalin, GHK-Cu, FOXO4-DRI or the growth hormone peptides has a proper aging study in people. The bottom is not one flat floor, though, and the difference matters. Klotho has gene evidence from thousands of people behind the target. Humanin and MOTS-c have studies that watched people, showing they fall with age. Epitalon and thymalin have open studies in people from one institute. GHK-Cu has skin cream studies in people, for a different result in a different body part. FOXO4-DRI has nothing from people at all. Only that last one deserves the word 'none'. The compounds with strong studies in people are approved drugs being tested for a new purpose, semaglutide and rapamycin, plus elamipretide in one rare disease. The strongest animal lifespan results belong to gene changes and to rapamycin, and none of those comes in a vial sold as a peptide. That is where the evidence stood in September 2026. More reading: NMN vs NR vs NAD and new compounds of 2026.